A 64-year-old woman with dyslipidemia, hypertension and type 2 diabetes plus an existing 4.0-mm × 28-mm bare-metal stent (BMS; Multilink Penta, Abbott Vascular, US) deployed over 10 years ago in the right coronary artery (RCA) was admitted to our emergency department with inferolateral and posterior ST-segment elevation acute myocardial infarction. Coronary angiography showed occlusion and thrombotic plaque in the mid RCA at the site of the prior stent implantation. After thrombectomy, optical coherence tomography (OCT) documented the presence of in-stent neoatherosclerosis with lipid-laden plaque, mild calcification, clustered macrophages and a disrupted thin-cap fibroatheroma (TCFA), a pattern similar to the morphology seen with typical native atherosclerosis (Figure 1 ).
Very, very late stent thrombosis triggered by in-stent neoatherosclerosis: optical coherence tomography findings
A 64-year-old woman with dyslipidemia, hypertension and type 2 diabetes plus an existing 4.0-mm × 28-mm bare-metal stent (BMS; Multilink Penta, Abbott Vascular, US) deployed over 10 years ago in the right coronary artery (RCA) was admitted to our emergency department with inferolateral and posterior ST-segment elevation acute myocardial infarction. Coronary angiography showed occlusion and thrombotic plaque in the mid RCA at the site of the prior stent implantation. After thrombectomy, optical coherence tomography (OCT) documented the presence of in-stent neoatherosclerosis with lipid-laden plaque, mild calcification, clustered macrophages and a disrupted thin-cap fibroatheroma (TCFA), a pattern similar to the morphology seen with typical native atherosclerosis (Figure 1) .
In-stent restenosis has widely been considered a stable process, showing an early peak of intimal hyperplasia followed by a stationary period generally after 1 year following stent implantation [1] . More recently, pathologic and in vivo intravascular imaging studies have challenged this finding by showing that lipid-rich plaque with macrophage infiltration and a necrotic core may occur inside the stent. This process of in-stent neoatherosclerosis occurs within months to a few years, compared with the decades that it generally takes for native disease to develop [2, 3] . Previous autopsy studies have shown a higher incidence of neoatherosclerosis in lesions treated with first-and second-generation drug-eluting stents (DES) compared with BMS (31% vs. 30% vs. 16%, respectively) [2, 3] . Of note, neoatherosclerosis presentation occurred on average at ~400 days after first-generation DES, ~200 days after second-generation DES, and ~2,000 days after BMS [2, 3] . Much like native coronary disease, the infiltration of foamy macrophages within the neointima could possibly cause thinning of the fibrous cap, leading to the development of a TCFA and complications of rupture with thrombosis, as seen in the present case.
The present report describes an unusual case of very, very late stent thrombosis -occurring more than a decade after BMS at 3,710 days -with evidence of neoatherosclerosis. This case highlights the need for continuous and perpetual secondary prevention of coronary artery disease in patients receiving percutaneous coronary intervention. The permanent presence of metallic foreign material in the vessel wall might indefinitely remain a potential trigger for stent failure at extended follow-up. 
